MicroRNA‐338‐5p reverses chemoresistance and inhibits invasion of esophageal squamous cell carcinoma cells by targeting Id‐1

5‐Fluorouracil (5‐FU) is a chemotherapeutic agent commonly used to treat esophageal squamous cell carcinoma (ESCC), but acquisition of chemoresistance frequently occurs and the underlying mechanisms are not fully understood. We found that microRNA (miR)‐338‐5p was underexpressed in ESCC cells with acquired 5‐FU chemoresistance. Forced expression of miR‐338‐5p in these cells resulted in downregulation of Id‐1, and restoration of both in vitro and in vivo sensitivity to 5‐FU treatment. The effects were abolished by reexpression of Id‐1. In contrast, miR‐338‐5p knockdown induced 5‐FU resistance in chemosensitive esophageal cell lines, and knockdown of both miR‐338‐5p and Id‐1 resensitized the cells to 5‐FU. In addition, miR‐338‐5p had suppressive effects on migration and invasion of ESCC cells. Luciferase reporter assay confirmed a direct interaction between miR‐338‐5p and the 3′‐UTR of Id‐1. We also found that miR‐338‐5p was significantly downregulated in tumor tissue and serum samples of patients with ESCC. Notably, low serum miR‐338‐5p expression level was associated with poorer survival and poor response to 5‐FU/cisplatin‐based neoadjuvant chemoradiotherapy. In summary, we found that miR‐338‐5p can modulate 5‐FU chemoresistance and inhibit invasion‐related functions in ESCC by negatively regulating Id‐1, and that serum miR‐338‐5p could be a novel noninvasive prognostic and predictive biomarker in ESCC.     

lncRNA CASC11通过EZH2调控PI3K/AKT通路促进食管鳞癌细胞顺铂耐药的机制研究

目的:探讨lncRNA CASC11对EZH2及磷脂酰肌醇-3-激酶（PI3K）/蛋白激酶B（AKT）信号轴的调控作用,及对食管鳞状细胞癌（ESCC）细胞顺铂（DDP）耐药性的影响。方法:取ESCC组织（76例）及癌旁组织（76例）,并体外培养正常食管黏膜上皮细胞（HET-1a）及ESCC细胞系（TE-1、Eca109、KYSE150、KYSE450和KYSE510）,qRT-PCR法检测lncRNA CASC11表达。逐步增加DDP浓度构建DDP耐药ESCC细胞（TE-1/DDP）,并随机分成si-NC组、si-lncRNA-CASC11组、si-lncRNA CASC11+IGF-1组、si-lncRNA CASC11+si-PTEN组,另取正常培养的TE-1细胞为Control组。克隆形成实验、CCK-8、流式细胞术、Transwell分别检测细胞增殖、耐药性、凋亡、迁移;qRT-PCR及Western Blot法检测lncRNA CASC11及EZH2、PI3K/AKT途径抑制物PTEN、PI3K/AKT通路蛋白、EMT标记蛋白（E-cadherin、N-cadherin）表达;RNA免疫沉淀（RIP）法检测PTEN对EZH2的调控关系;染色质免疫沉淀（ChIP）检测EZH2、PTEN、lncRNA CASC11三者间调控关系。将lncRNA CASC11敲低TE-1/DDP细胞接种于裸鼠皮下并进行DDP干预,检测瘤体体积及瘤体重量,免疫组化分析Ki67活性。结果:lncRNA CASC11在ESCC癌组织、细胞系和TE-1/DDP细胞中的表达均显著升高（P＜0.05）。敲低lncRNA CASC11可抑制TE-1/DDP细胞增殖、迁移及EMT进程,触发细胞凋亡,并抑制细胞耐药及EZH2-PI3K/AKT生存途径的活化（P＜0.05）。裸鼠荷瘤实验证实敲低lncRNA CASC11可增加TE-1细胞对DDP的敏感性（P＜0.05）。EZH2可结合PTEN启动子并降低PTEN表达,而敲低lncRNA CASC11可减少EZH2与PTEN启动子区域的结合。PTEN敲低或给予IGF-1干预,均可部分逆转lncRNA CASC11敲低发挥的抗癌及抗DDP耐药性产生的作用（P＜0.05）。结论:lncRNA CASC11可通过与EZH2相互作用来沉默PTEN,激活PI3K/AKT介导的细胞存活途径,提高ESCC对DDP的耐药性,而敲低lncRNA CASC11可降低癌细胞对DDP的耐药性,增强ESCC对DDP的化疗敏感性。     

lncRNA NUP50-AS1 在食管鳞癌组织中的表达及其对Eca109 细胞恶性生物学行为的影响

目的:探讨长链非编码RNA（long non-coding RNA, lncRNA）NUP50-AS1 在食管鳞状细胞癌（esophageal squamous cell cancer, ESCC）组织及细胞株中的表达及其对人食管癌Eca109 细胞增殖、迁移和侵袭的影响。方法：选取自2015 年1 月至2016 年12 月河北医科大学第四医院生物标本库的49 例ESCC手术患者的癌组织和相应癌旁组织,qRT-PCR检测ESCC癌组织、癌旁组织及5 种食管癌细胞株（TE1、TE13、Eca109、Kyse150 和Kyse170）中NUP50-AS1 表达水平。shRNA 转染NUP50-AS1 后,选用sh2 -NUP50-AS1 进行后续功能实验。采用MTS法、克隆形成实验检测敲减NUP50-AS1 表达对Eca109 细胞增殖的影响,划痕实验检测敲减NUP50-AS1 表达对细胞迁移的影响,Transwell 小室实验检测敲减NUP50-AS1 表达对细胞侵袭的影响。结果：NUP50-AS1 在ESCC组织中的相对表达量显著高于癌旁组织(2.003±0.870 vs 1.000±0.000,P<0.05）;NUP50-AS1 在ESCC组织中的表达水平与淋巴结转移及TNM分期相关（均P<0.01）,NUP50-AS1 在5 株食管癌细胞系中相对表达量均明显上调（P<0.05）,其中Eca109 细胞的NUP50-AS1 表达水平最高。转染后,sh2-NUP50-AS1 转染组干扰效率最高,敲低NUP50-AS1 可明显抑制Eca109 细胞增殖、迁移和侵袭能力。结论：ESCC组织中lncRNA NUP50-AS1 表达明显高于癌旁组织,且与癌症分期和淋巴结转移有关,敲减其表达明显抑制食管癌细胞增殖、迁移和侵袭能力,NUP50-AS1 的高表达可能与ESCC的发生发展密切相关。     

Overexpression of the Long Noncoding RNA FOXD2-AS1 Promotes Cisplatin Resistance in Esophageal Squamous Cell Carcinoma Through the miR-195/Akt/mTOR Axis

Emerging evidence has demonstrated that long noncoding RNAs (lncRNAs) mediate the development of esophageal squamous cell carcinoma (ESCC) via various pathophysiological pathways. This study explored the impact of the lncRNA FOXD2-AS1 on cisplatin resistance in ESCC and its possible mechanisms. Upregulation of FOXD2-AS was detected in patients with ESCC and ESCC cells that are resistant to cisplatin. In an in vitro assay, knockdown of FOXD2-AS1 noticeably inhibited cell invasion and growth, triggered cell death, and repressed the stimulation of the Akt/mTOR axis in cisplatin-resistant ESCC cells (TE-1/DDP). Conversely, the overexpression of FOXD2-AS1 remarkably increased cell invasion and growth, repressed cell death, and triggered the stimulation of the Akt/mTOR axis in TE-1/DDP cells. These findings, along with bioinformatics and validation tests, showed that FOXD2-AS1 targeted miR-195 by acting as a competing endogenous RNA. FOXD2-AS1/miR-195/Akt/mTOR axis plays a crucial role in resistance to cisplatin in ESCC cells, offering an innovative strategy to treat ESCC.     

Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma

Ovarian clear cell carcinoma (OCCC) is a type of epithelial ovarian cancer that is strongly associated with endometriosis, resistance against conventional chemotherapy and thus poorer prognosis. The expression of inhibitory member of the ASPP family proteins (iASPP) and Polo‐like kinase (PLK)1 were significantly higher in OCCC compared to benign cystadenomas and endometriosis. Both protein expressions were found to correlate with chemoresistance in patients with OCCC while high iASPP expression alone was significantly associated with a poor patient survival. The growth of OCCC cell lines, OVTOKO and KK, were inhibited after iASPP silencing. Such effect was related to senescence triggering as evidenced by increased SA‐β‐Gal staining and p21^WAF1/Cip1 expression. Moreover, knockdown of iASPP induced PLK1 downregulation, whereas either genes’ silencing sensitized the cells in response to cisplatin treatment. More prominent apoptosis was induced by cisplatin in OCCC cells after the knockdown of either iASPP or PLK1 as evidenced by the formation of more cleaved caspase 3. Heightened chemosensitivity to cisplatin after iASPP knockdown was further demonstrated in in vivo xenograft model. Additionally, both iASPP and PLK1 were shown to regulate autophagic flux as the induction of LC3B‐II and LC3 puncta were much less in OCCC cells with either knockdown. Importantly, inhibition of autophagy also enhanced chemosensitivity to cisplatin in OCCC cells. These findings strongly imply that iASPP and PLK1 affect the chemoresistance of OCCC via the regulation of autophagy and apoptosis. Both iASPP and PLK1 can be potential therapeutic targets for treating OCCC in combination with conventional chemotherapy.     

PTENP1 inhibits the growth of esophageal squamous cell carcinoma by regulating SOCS6 expression and correlates with disease prognosis

PTEN pseudogene (PTENP1) has a tumor suppressive role in multiple cancers. However, its involvement in esophageal squamous cell carcinoma (ESCC) remains largely unknown. In this study, we set out to identify the role of PTENP1 in the development of ESCC. Gene Expression Omnibus database was employed to investigate the expression of PTENP1 in ESCC. sRNA target Database (StarBase v2.0) was used to query the downstream of PTENP1. Next, both in vitro and in vivo experiments were employed to explore the function. Cell proliferation was evaluated by CCK‐8, soft agar, and colony formation assays. Expression of relative genes was assessed by quantitative real‐time PCR (qRT‐PCR) and Western blotting. 3′UTR luciferase assay was used to confirm the miRNA binding. The clinical significance of PTENP1 was further validated by immunohistochemistry (IHC) and correlation with clinicopathological indicators in additional samples (n = 93). We found expression of PTENP1 in ESCC was lower than that in the corresponding adjacent normal tissues (n = 17). Overexpression of PTENP1 in Eca109 and TE‐1 cells resulted in inhibited proliferation and altered expression of SOCS6‐p‐STAT3‐HIF‐1α pathway both in vitro and in vivo. Subsequent IHC reported a similar trend in human ESCC samples. 3′UTR luciferase assay demonstrated that PTENP1 3′UTR decoyed miR‐17‐5p from binding to SOCS6. Moreover, PTENP1 expression was correlated with clinicopathological indicators to varying degrees, including histological grade, TNM stage, infiltration depth, lymph node metastasis, and overall survival. Taken together, these results suggested an anti‐oncogenic role of PTENP1. Meanwhile, PTENP1 may also serve as a candidate of prognostic indicator for ESCC patients.     

BNC1调控食管鳞状细胞癌细胞的恶性生物学行为及其可能的作用机制

目的：探讨碱性核蛋白1(BNC1)对食管鳞状细胞癌（ESCC）细胞增殖、迁移、侵袭、细胞周期和凋亡的影响及其作用机制。方法：通过q PCR法检测ESCC细胞和正常食管上皮细胞中BNC1 m RNA的表达水平,免疫组织化学染色法检测10例ESCC患者癌及癌旁组织中BNC1的蛋白表达水平。利用si RNA敲低BNC1在KYSE-150和KYSE-30细胞中的表达,CCK-8法、划痕愈合实验、Transwell实验和流式细胞术检测BNC1对细胞增殖、迁移、侵袭、细胞周期和凋亡等的影响。通过CHIP-seq实验和GEPIA在线网站数据分析并结合敲低BNC1后的转录组测序数据分析筛选BNC1调控的下游靶基因,q PCR法验证BNC1敲低后靶基因的表达变化,并用双荧光素酶报告基因实验验证BNC1对靶基因的调控作用。结果：BNC1 m RNA和蛋白水平在ESCC组织中较癌旁组织高表达（均P<0.01）。敲低BNC1可明显抑制KYSE-150、KYSE-30细胞的增殖、迁移和侵袭能力（P<0.05或P<0.01）,将细胞阻滞于G1期并促进细胞的凋亡（均P<0.01）。CHIP-...     

Long non‐coding RNA urothelial cancer‐associated 1 promotes bladder cancer cell migration and invasion by way of the hsa‐miR‐145–ZEB1/2–FSCN1 pathway

Numerous studies suggest that several long non‐coding RNAs (lncRNAs) play critical roles in bladder cancer development and progression. Long non‐coding RNA urothelial cancer‐associated 1 (lncRNA‐UCA1) is highly expressed in bladder cancer tissues and cells, and it has been shown to play an important role in regulating aggressive phenotypes of bladder cancer cells. However, little is known about the molecular mechanism of lncRNA‐UCA1‐mediated bladder cancer cell migration and invasion. Here, we show that overexpression of lncRNA‐UCA1 could induce EMT and increase the migratory and invasive abilities of bladder cancer cells. Mechanistically, lncRNA‐UCA1 induced EMT of bladder cancer cells by upregulating the expression levels of zinc finger E‐box binding homeobox 1 and 2 (ZEB1 and ZEB2), and regulated bladder cancer cell migration and invasion by tumor suppressive hsa‐miR‐145 and its target gene the actin‐binding protein fascin homologue 1 (FSCN1). Furthermore, we also observed a positive correlation between lncRNA‐UCA1 and ZEB1/2 expression, and a negative correlation between lncRNA‐UCA1 and hsa‐miR‐145 expression in bladder cancer specimens. Importantly, we found that lncRNA‐UCA1 repressed hsa‐miR‐145 expression to upregulate ZEB1/2, whereas the suppression of hsa‐miR‐145 could upregulate lncRNA‐UCA1 expression in bladder cancer cells. Moreover, the binding site for hsa‐miR‐145 within exons 2 and 3 of lncRNA‐UCA1 contributed to the reciprocal negative regulation of lncRNA‐UCA1 and hsa‐miR‐145. Taken together, our results identified that lncRNA‐UCA1 enhances bladder cancer cell migration and invasion in part through the hsa‐miR‐145/ZEB1/2/FSCN1 pathway. Therefore, lncRNA‐UCA1 might act as a promising therapeutic target for the invasion and metastasis of bladder cancer.     

LncRNA LINP1 regulates acute myeloid leukemia progression via HNF4α/AMPK/WNT5A signaling pathway

LncRNAs play critical roles in various pathophysiological and biological processes, such as protein translation, RNA splicing, and epigenetic modification. Indeed, abundant evidences demonstrated that lncRNA act as competing endogenous RNAs (ceRNAs) to participate in tumorigenesis. However, little is known about the underlying function of lncRNA in nonhomologous end joining (NHEJ) pathway 1 (LINP1) in pediatric and adolescent acute myeloid leukemia (AML). The expression of LINP1 was examined in AML patient samples by qRT‐PCR. Cell proliferation was examined by CCK‐8 and Edu assays. β‐Galactosidase senescence assay, mGlucose uptake assay, lactate production assay, and Gene Ontology (GO) analysis were performed for functional analysis. We found that LINP1 was significantly overexpressed in AML patients at diagnosis, whereas downregulated after complete remission (CR). Furthermore, knockdown of LINP1 expression remarkably suppressed glucose uptake and AML cell maintenance. Mechanistically, LINP1 was found to inhibit the glucose metabolism by suppressing the expression of HNF4a. Both LINP1 and HNF4a knockdown reduced the expression levels of AMPK phosphorylation and WNT5A, indicating for the first time that LINP1 strengthened the HNF4a‐AMPK/WNT5A signaling pathway involved in cell glucose metabolism modulation and AML cell survival. Taken together, our results indicated that LINP1 promotes the malignant phenotype of AML cells and stimulates glucose metabolism, which can be regarded as a potential prognostic marker and therapeutic target for AML.     

lncRNA SNHG6靶向miR‐485‐3p对宫颈癌SiHa细胞增殖及放疗敏感性的影响

目的 探讨长链非编码RNA（lncRNA）SNHG6对宫颈癌SiHa细胞增殖和放疗敏感性的影响及其潜在的作用机制。方法 检测lncRNA SNHG6、miR‐485‐3p在宫颈癌组织、癌旁组织、SiHa细胞及X线照射的SiHa细胞中的表达。分析lncRNA SNHG6与miR‐485‐3p之间的关系。过表达或敲降SNHG6、miR‐485‐3p后,MTT、Transwell迁移实验和流式细胞仪检测细胞增殖能力、侵袭数目和凋亡率。分析miR‐485‐3p对Wnt/β‐catenin通路的影响以及XAV939对SiHa细胞增殖及放疗敏感性的影响。结果 lncRNA SNHG6在宫颈癌组织和SiHa细胞中高表达,在X线照射的SiHa细胞中低表达,miR‐485‐3p在宫颈癌组织和SiHa细胞中低表达,在X线照射的SiHa细胞中高表达。lncRNA SNHG6靶向miR‐485‐3p。下调lncRNA SNHG6表达抑制了细胞增殖和侵袭,增强了其对X线的放疗敏感性,而miR‐485‐3p抑制剂转染细胞后则起到相反作用。上调lncRNA SNHG6通过miR‐485‐3p促进了SiHa细胞的增殖与侵袭,降低了放疗敏感性。下调miR‐485‐3p激活了Wnt/β‐catenin通路,促进了SiHa的细胞增殖和侵袭,降低了其对X线的放疗敏感性。结论 过表达lncRNA SNHG6靶向miR‐485‐3p激活Wnt/β‐catenin通路调控SiHa细胞的增殖及其放疗敏感性。     

lncRNA SNHG6靶向miR‐485‐3p对宫颈癌SiHa细胞增殖及放疗敏感性的影响

目的 探讨长链非编码RNA（lncRNA）SNHG6对宫颈癌SiHa细胞增殖和放疗敏感性的影响及其潜在的作用机制。方法 检测lncRNA SNHG6、miR‐485‐3p在宫颈癌组织、癌旁组织、SiHa细胞及X线照射的SiHa细胞中的表达。分析lncRNA SNHG6与miR‐485‐3p之间的关系。过表达或敲降SNHG6、miR‐485‐3p后,MTT、Transwell迁移实验和流式细胞仪检测细胞增殖能力、侵袭数目和凋亡率。分析miR‐485‐3p对Wnt/β‐catenin通路的影响以及XAV939对SiHa细胞增殖及放疗敏感性的影响。结果 lncRNA SNHG6在宫颈癌组织和SiHa细胞中高表达,在X线照射的SiHa细胞中低表达,miR‐485‐3p在宫颈癌组织和SiHa细胞中低表达,在X线照射的SiHa细胞中高表达。lncRNA SNHG6靶向miR‐485‐3p。下调lncRNA SNHG6表达抑制了细胞增殖和侵袭,增强了其对X线的放疗敏感性,而miR‐485‐3p抑制剂转染细胞后则起到相反作用。上调lncRNA SNHG6通过miR‐485‐3p促进了SiHa细胞的增殖与侵袭,降低了放疗敏感性。下调miR‐485‐3p激活了Wnt/β‐catenin通路,促进了SiHa的细胞增殖和侵袭,降低了其对X线的放疗敏感性。结论 过表达lncRNA SNHG6靶向miR‐485‐3p激活Wnt/β‐catenin通路调控SiHa细胞的增殖及其放疗敏感性。     

lncRNA DGCR5通过上调EGFR表达促进食管鳞状细胞癌TE1细胞的恶性生物学行为

目的：探讨长链非编码 RNA（long non-coding RNA,lncRNA）DiGeorge 综合征临界区基因 5（digeorge syndrome critical region gene 5,DGCR5）对食管鳞状细胞癌（esophageal squamous cell carcinoma,ESCC）TE1细胞增殖、迁移和侵袭的影响及其机制。方法：采用qPCR检测ESCC细胞系 TE1、Yes-2、KYSE150 和 Eca9706 中 DGCR5 的表达水平。将siRNA-DGCR5（si-DGCR5）和阴性对照组（si-NC）质粒转染进TE1细胞,用CCK-8、划痕愈合、Transwell小室法分别检测TE1细胞增殖、迁移和侵袭能力。依据GEPIA数据库资料分析食管癌组织中 DGCR5 表达与细胞表皮生长因子受体（epidermal growth factor receptor,EGFR）的相关性,并用qPCR和Western blotting（WB）检测ESCC细胞系中EGFR mRNA和蛋白表达水平,进一步用WB实验检测转染 si-DGCR5 前后 TE1细胞中EGFR蛋白的表达水平。结果：DGCR5 在 ESCC 细胞系中均高表达（均 P<0.01）,转染siDGCR5组TE1细胞中DGCR5的表达水平明显低于si-NC组（P<0.01）。敲低DGCR5后,TE1细胞的增殖、侵袭和迁移能力显著低于si-NC组细胞（均 P<0.01）。GEPIA 数据库的分析显示,食管癌组织中 DGCR5 表达水平与 EGFR 的表达呈正相关（P<0.01）。敲低DGCR5后TE1细胞中EGFR蛋白表达水平明显下降（P<0.01）。结论：lncRNA DGCR5在ESCC细胞中呈高表达,可能通过上调EGFR表达来促进TE1细胞的增殖、侵袭和迁移等恶性生物学行为。     

Polo-Like Kinase 1 Regulates Chromosomal Instability and Paclitaxel Resistance in Breast Cancer Cells

PurposeChromosomal instability (CIN) contributes to intercellular genetic heterogeneity and has been implicated in paclitaxel (PTX) resistance in breast cancer. In this study, we explored polo-like kinase 1 (PLK1) as an important regulator of mitotic integrity and as a useful predictive biomarker for PTX resistance in breast cancer.MethodsWe performed PTX resistance screening using the human kinome CRISPR/Cas9 library in breast cancer cells. In vitro cell proliferation and apoptosis assays and in vivo xenograft experiments were performed to determine the effects of PLK1 on breast cancer cells. Immunofluorescence microscopy was used to measure the degree of multipolar cell division.ResultsKinome-wide CRISPR/Cas9 screening identified various kinases involved in PTX resistance in breast cancer cells; among these, PLK1 was chosen for further experiments. PLK1 knockdown inhibited the proliferation of MDA-MB-231 and MDA-MB-468 cells in vitro and in vivo. Moreover, PLK1 silencing sensitized breast cancer cells and mouse xenograft tumor models to PTX cytotoxicity. Silencing of PLK1 induced the formation of multipolar spindles and increased the percentage of multipolar cells. In addition, PLK1 silencing resulted in the downregulation of BubR1 and Mad2 in breast cancer cells. Furthermore, PLK1 upregulation in primary breast cancer was associated with decreased overall patient survival based on the analysis of The Cancer Genome Atlas and Molecular Taxonomy of Breast Cancer International Consortium databases.ConclusionPLK1 plays an important role in PTX resistance by regulating CIN in breast cancer cells. Targeting PLK1 may be an effective treatment strategy for PTX-resistant breast cancers.     

Id‐1 promotes tumorigenicity and metastasis of human esophageal cancer cells through activation of PI3K/AKT signaling pathway

Id‐1 (inhibitor of differentiation or DNA binding) is a helix‐loop‐helix protein that is overexpressed in many types of cancer including esophageal squamous cell carcinoma (ESCC). We previously reported that ectopic Id‐1 expression activates the phosphatidylinositol‐3‐kinase (PI3K)/protein kinase B (AKT) signaling pathway in human esophageal cancer cells. In this study, we confirmed a positive correlation between Id‐1 and phospho‐AKT (Ser473) expressions in ESCC cell lines, as well as in ESCC on a tissue microarray. To investigate the significance of Id‐1 in esophageal cancer progression, ESCC cells with stable ectopic Id‐1 expression were inoculated subcutaneously into the flank of nude mice and were found to form larger tumors that showed elevated Ki‐67 proliferation index and increased angiogenesis, as well as reduced apoptosis, compared with control cells expressing the empty vector.The Id‐1‐overexpressing cells also exhibited enhanced metastatic potential in the experimental metastasis assay. Treatment with the PI3K inhibitor LY294002 attenuated the tumor promotion effects of Id‐1, indicating that the effects were mediated by the PI3K/AKT signaling pathway. In addition, our in vitro experiments showed that ectopic Id‐1 expression altered the expression levels of markers associated with epithelial–mesenchymal transition and enhanced the migration ability of esophageal cancer cells. The Id‐1‐overexpressing ESCC cells also exhibited increased invasive potential, which was in part due to PI3K/AKT‐dependent modulation of matrix metalloproteinase‐9 expression. In conclusion, our results provide the first evidence that Id‐1 promotes tumorigenicity and metastasis of human esophageal cancer in vivo and that the PI3K inhibitor LY294002 can attenuate these effects. © 2009 UICC     

长链非编码RNA ZEB1-AS1促进食管鳞癌侵袭转移

背景与目的：长链非编码RNA（long non-coding RNA,lncRNA）锌指E-盒结合同源异形盒1-反义链1（Zinc finger E-box binding homeobox 1 antisense 1,ZEB1-AS1）在多种肿瘤中高表达,与肿瘤患者临床病理学特征及预后相关,但其在食管鳞癌（esophageal squamous cell carcinoma,ESCC）中的作用及其机制尚不清楚。从细胞与分子生物学水平探讨lncRNA ZEB1-AS1在ESCC细胞侵袭转移中的作用。方法：通过实时荧光定量聚合酶链反应（real-time fluorescence quantitative polymerase chain reaction,RTFQ-PCR）方法检测9株ESCC细胞株中lncRNA ZEB1-AS1的表达水平,筛选出一株高表达细胞株。采用小干扰RNA（small interference RNA,siRNA）转染Eca-109细胞,分成干扰组（siZEB1-AS1）、干扰对照组（siNC）和空白组（Eca-109）。采用RTFQ-PCR方法检测lncRNA ZEB1-AS1的表达水平,采用细胞计数试剂盒（cell counting kit-8,CCK-8）实验检测细胞增殖能力情况,采用划痕实验和Transwell实验检测细胞迁移和侵袭能力情况,采用RTFQ-PCR方法和蛋白质印迹法（Western blot）检测ZEB1的表达水平。结果：9株ESCC细胞株中,Eca-109细胞中lncRNA ZEB1-AS1表达水平最高。siRNA 抑制lncRNA ZEB1-AS1表达,降至对照组的57%。与对照组细胞相比,lncRNA ZEB1-AS1不影响Eca-109细胞增殖,但是能显著促进Eca-109细胞迁移和侵袭。lncRNA ZEB1-AS1上调ZEB1 mRNA和蛋白的表达。结论：lncRNA ZEB1-AS1通过上调ZEB1促进ESCC迁移、侵袭,lncRNA ZEB1-AS1/ZEB1或许可以作为ESCC治疗的潜在靶点。